Please ensure Javascript is enabled for purposes of website accessibility

Science Arena Investors Need to Know

By Max Macaluso – Updated Apr 7, 2017 at 12:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Arena Pharmaceuticals won approval from the Food and Drug Administration for its obesity drug, Belviq, in June, and its share price has jumped more than 380% year to date. Shareholders have undoubtedly enjoyed this return, but where will Arena go from here? How will Belviq fare against VIVUS' rival obesity drug, Qsymia? Will Orexigen's weight loss candidate, Contrave -- which could be FDA-approved soon -- ultimately prove to be the long-term winner in this market?

These are difficult questions to answer, but understanding the science behind these drugs can help you read through press releases and make better investing decisions. In this video, health care analyst Max Macaluso discusses how Belviq works biologically and notes a few things to watch in Arena's upcoming post-marketing studies.

Arena is confronting significant challenges as it prepares to launch Belviq in 2013. In our brand new premium research report on Arena Pharmaceuticals, senior biotech analyst Brian Orelli walks investors through both the opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.

Max Macaluso has no positions in the stocks mentioned above. Feel free to send him an email or contact him on Twitter @TMFMassimo if you have questions for him to answer in this new video series. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arena Pharmaceuticals Stock Quote
Arena Pharmaceuticals
ARNA
VIVUS Stock Quote
VIVUS
VVUS

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.